FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC

Regulatory Approvals — FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC  Targeted Onc

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. November 17, 2026.

By